Multispecialty Clinical Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: Optimizing Cardiometabolic Risk

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has emerged as a rapidly expanding global clinical challenge, closely intertwined with obesity, type 2 diabetes mellitus, chronic kidney disease, and cardiovascular complications. Given the convergence of metabolic, hepatic and cardiac pathways, an integrated clinical strategy is increasingly essential. This review highlights how coordinated management across various specialties can refine risk stratification, improve diagnostic accuracy, and enhance long-term outcomes for patients with MASLD. The growing epidemiological burden is paralleled by escalating risks of heart failure, arrhythmias and progressive liver injury. Shared mechanisms including insulin resistance, systemic inflammation and lipotoxicity reinforce the need for comprehensive evaluations using non-invasive fibrosis scores, cardiometabolic biomarkers and structured surveillance protocols. Evidence supports the incorporation of lifestyle interventions, GLP-1 receptor agonists, SGLT2 inhibitors and tailored cardiometabolic monitoring within multidisciplinary clinics. Despite barriers such as heterogeneous referral patterns and limited cross-specialty coordination, interdisciplinary models consistently demonstrate superior early detection and more precise therapeutic planning. Moving forward, standardized follow-up pathways, longitudinal risk-based surveillance, and AI-assisted prediction tools may substantially improve personalized care and reduce morbidity in this high-risk population.